The global biopharmaceutical contract manufacturing market size was valued at USD 44.53 billion in 2025 and is projected to grow from USD 49.52 billion in 2026 to USD 115.86 billion by 2034, registering a CAGR of 11.21% during the forecast period from 2026 to 2034. North America dominated the biopharmaceutical contract manufacturing market with a market share of 39.2% in 2025.
Biopharmaceutical contract manufacturing involves outsourcing the production of biologic medicines to specialized companies with advanced manufacturing facilities and technical expertise. These services cover products such as vaccines, monoclonal antibodies, recombinant proteins, and cell-based therapies. Demand is growing as pharmaceutical companies focus on reducing production costs, accessing specialized technologies, expanding manufacturing capacity, and meeting the increasing need for biologic drugs.
Download a Free Sample To learn more about this report,
Growing Shift Toward Integrated End-to-End Biologics Manufacturing
The biopharmaceutical contract manufacturing market is shifting toward integrated CDMO models that combine process development, clinical manufacturing, commercial production, analytical testing, and other manufacturing activities under coordinated service structures. Biopharmaceutical companies can reduce technology-transfer complexity and the need to establish internal infrastructure by using providers with capabilities spanning multiple stages of development. This is increasing the competitive importance of manufacturing scale, regulatory experience, and the ability to support programs from early development through commercialization. FDA guidance recognizes contract manufacturing arrangements as an established mechanism for sharing manufacturing activities and improving manufacturing flexibility.
Increasing Adoption of Advanced Manufacturing Platforms for Complex Biologics
The market is increasingly moving toward advanced manufacturing approaches designed for complex and rapidly developing biologic modalities. Single-use systems, closed processing, advanced process controls, and digital quality technologies can improve manufacturing flexibility while reducing the infrastructure burden associated with conventional facilities. These capabilities are particularly relevant as contract manufacturers serve diverse pipelines with varying production scales and technical requirements.
Expansion of Biologic Development Pipelines Increases Outsourced Manufacturing Demand
The continued development of biologics, including monoclonal antibodies, recombinant proteins, vaccines, and advanced therapies, is increasing demand for specialized manufacturing capacity. Many biotechnology companies do not maintain the capital-intensive facilities, specialized equipment, and manufacturing expertise required to produce biologics at clinical or commercial scale. Contract manufacturers provide access to qualified infrastructure and technical capabilities, allowing sponsors to advance programs without building equivalent internal capacity.
High Capital Requirements for Specialized Biomanufacturing Facilities Limit Service Accessibility
Biopharmaceutical manufacturing requires specialized bioreactors, downstream-processing equipment, cleanrooms, analytical capabilities, quality systems, and validated processes. These requirements create high capital commitments for CDMOs and can increase the cost of outsourced manufacturing services, particularly for smaller biotechnology companies with limited funding. Consequently, some early-stage developers may face difficulty securing manufacturing capacity that matches their technical and financial requirements.
Expansion of Cell and Gene Therapy Manufacturing Creates New CDMO Opportunities
The growing development of cell and gene therapies is creating opportunities for contract manufacturers with specialized capabilities in viral vectors, cell processing, aseptic operations, analytical testing, and regulatory support. These therapies require manufacturing approaches that differ substantially from conventional biologics, increasing the value of CDMOs with dedicated expertise and flexible facilities. Providers capable of supporting developers from clinical-stage production through commercialization can capture demand from biotechnology companies that lack specialized internal manufacturing infrastructure.
Complex Technology Transfer and Quality Oversight Challenge Contract Manufacturing Reliability
Transferring a biologic manufacturing process from a sponsor to a CDMO requires successful transfer of process knowledge, analytical methods, specifications, equipment requirements, and quality controls. Differences between development and manufacturing facilities can create variability or delays, while the sponsor remains responsible for ensuring that outsourced operations meet applicable quality requirements. Maintaining consistent communication, documentation, validation, and oversight across organizations therefore remains a major operational challenge.
Process Development Segment Dominated the Market with 30.4% Share in 2025
The process development segment dominated the global biopharmaceutical contract manufacturing market with a 30.4% share in 2025. Process development services are essential for designing scalable, efficient, and reproducible manufacturing processes for complex biological products. Growing outsourcing by pharmaceutical and biotechnology companies continues to support demand for specialized development capabilities.
Fill & finish operations accounted for 27.6% and are growing at the highest CAGR of 12.4%, supported by rising biologics production and demand for sterile manufacturing. Analytical & QC studies remain important for product quality and regulatory compliance, while packaging & labelling services support final product preparation. These outsourced services are contributing to biopharmaceutical contract manufacturing market growth.
Request Customizationto receive a tailored report.
Upstream Segment Dominated the Market with 56.8% Share in 2025
The upstream segment dominated the process development category with a 56.8% share in 2025. Upstream processing covers important activities such as cell culture development, media optimization, and bioreactor operations required for producing biological molecules. Increasing production of monoclonal antibodies, recombinant proteins, and other biologics continues to strengthen demand for upstream expertise.
The downstream segment accounted for 43.2% and is growing at a CAGR of 11.4%. Downstream processing involves purification, separation, and recovery of biological products to achieve required purity and quality levels. Increasing complexity of biologic molecules is supporting continued investment in both upstream and downstream processes.
Mammalian Segment Dominated the Market with 68.4% Share in 2025
The mammalian segment dominated the global biopharmaceutical contract manufacturing market with a 68.4% share in 2025. Mammalian cell systems are widely used to manufacture complex biologics because they can produce proteins with appropriate folding and post-translational modifications. Their extensive use in monoclonal antibody and recombinant protein production supports the segment's leading position.
Non-mammalian sources accounted for 31.6% and are growing at a CAGR of 9.8%. These systems can provide advantages such as faster production cycles and lower manufacturing costs for suitable biological products.
Biologics Segment Dominated the Market with 76.3% Share in 2025
The biologics segment dominated the global biopharmaceutical contract manufacturing market with a 76.3% share in 2025. Growing development and commercialization of monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies have increased the need for specialized manufacturing infrastructure and technical expertise.
Biosimilars accounted for 23.7% and are growing at the highest CAGR of 12.6%. Expanding biosimilar pipelines, patent expirations of major biologic products, and increasing demand for cost-effective biological therapies are encouraging companies to outsource production to experienced contract manufacturers.
Monoclonal Antibodies Segment Dominated the Market with 38.5% Share in 2025
The monoclonal antibodies segment dominated the biologics category with a 38.5% share in 2025. Monoclonal antibodies are extensively developed for oncology, autoimmune diseases, and other therapeutic areas, creating strong demand for specialized large-scale manufacturing capabilities.
Recombinant proteins and vaccines also represent important segments due to their broad therapeutic and preventive applications. Cell and gene therapy is growing at the highest CAGR of 16.5%, driven by expanding development pipelines and increasing demand for highly specialized manufacturing processes.
Therapeutic peptides & proteins and other biologics further contribute to demand for flexible contract manufacturing capacity.
Drug Substance Segment Dominated the Market with 60.8% Share in 2025
The drug substance segment dominated the global biopharmaceutical contract manufacturing market with a 60.8% share in 2025. Drug substance manufacturing includes complex production, purification, and processing activities that require specialized facilities, equipment, and technical expertise. Outsourcing these activities allows biopharmaceutical companies to access manufacturing capacity without developing extensive in-house infrastructure.
Finished drug products accounted for 39.2% and are growing at a higher CAGR of 11.4%. Increasing requirements for formulation, sterile filling, finishing, and final product preparation are supporting greater outsourcing of finished drug manufacturing.
Oncology Segment Dominated the Market with 34.6% Share in 2025
The oncology segment dominated the global biopharmaceutical contract manufacturing market with a 34.6% share in 2025. Strong development pipelines for monoclonal antibodies, targeted biologics, cell therapies, and other cancer treatments create substantial requirements for specialized manufacturing services. Continued investment in oncology drug development supports the segment's leading position.
Autoimmune and infectious diseases also generate significant demand for biologics manufacturing, while neurology is growing at a CAGR of 11.8%. Metabolic and cardiovascular diseases further contribute to outsourced production requirements.
Oncology is also growing at the highest CAGR of 12.5% among the listed therapeutic areas, supported by continued innovation and development of new biological cancer treatments.
Speak to an Analystto discuss market opportunities.
North America biopharmaceutical contract manufacturing market accounted for 39.2% of the global market, reaching USD 17.46 billion in 2025, and is projected to grow at a CAGR of 10.1% during the forecast period. Strong biologics development, high pharmaceutical R&D spending, and increasing outsourcing of complex manufacturing processes are supporting regional growth. Biopharmaceutical companies are increasingly working with contract manufacturers to access specialized production capabilities, reduce capital investment, and accelerate commercialization.
The US market was valued at USD 14.84 billion in 2025, making it the largest contributor in North America. A strong biotechnology industry, extensive biologics pipelines, and growing outsourcing of manufacturing activities continue to support demand for contract manufacturing services.
Canada's market reached USD 2.62 billion in 2025. Expansion of biotechnology research, increasing investment in biologics manufacturing, and growing collaboration between drug developers and contract manufacturers are supporting market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe biopharmaceutical contract manufacturing market accounted for 28.1% of the global market, reaching USD 12.51 billion in 2025, and is expected to register a CAGR of 9.7% during the forecast period. Strong pharmaceutical manufacturing capabilities, established regulatory standards, and increasing production of biologics and biosimilars are supporting regional demand. Growing investment in advanced manufacturing facilities and flexible production capacity is also strengthening the regional contract manufacturing industry.
Germany's market accounted for USD 3.63 billion in 2025. Strong pharmaceutical manufacturing infrastructure, advanced biotechnology capabilities, and increasing production of biologic medicines continue to support market growth.
The UK market was valued at USD 2.50 billion in 2025. A developed life sciences sector, growing biologics research, and increasing outsourcing of manufacturing activities continue to contribute to market development.
Asia Pacific biopharmaceutical contract manufacturing market accounted for 24.5% of the global market, reaching USD 10.91 billion in 2025, and is projected to register the fastest regional CAGR of 13.6% during the forecast period. Competitive manufacturing costs, expanding biologics production capacity, increasing pharmaceutical investment, and a growing number of biotechnology companies are driving regional demand. Contract manufacturers are expanding facilities and advanced production capabilities to serve both domestic and international drug developers.
Japan's market generated USD 1.96 billion in 2025. Advanced pharmaceutical manufacturing, strong quality standards, and increasing development of biologics and innovative therapies continue to support demand for contract manufacturing services.
China's market accounted for USD 5.67 billion in 2025, making it a major contributor within Asia Pacific. Rapid expansion of biotechnology, growing biologics pipelines, increasing manufacturing capacity, and competitive production capabilities continue to drive market growth.
Middle East & Africa biopharmaceutical contract manufacturing market accounted for 3.5% of the global market, reaching USD 1.56 billion in 2025, and is anticipated to grow at a CAGR of 9.4% during the forecast period. Increasing pharmaceutical investment, development of local manufacturing capacity, and efforts to reduce dependence on imported medicines are supporting regional growth. Expansion of biotechnology and advanced healthcare infrastructure is also creating opportunities for contract manufacturers.
The UAE market was valued at USD 0.56 billion in 2025. Investment in pharmaceutical and biotechnology manufacturing, development of advanced healthcare infrastructure, and growing efforts to establish local production capabilities continue to support market growth.
The global Biopharmaceutical Contract Manufacturing market is highly competitive, driven by growing biologics pipelines, increasing outsourcing by pharmaceutical companies, and rising demand for flexible manufacturing capacity. Key players include AGC Biologics, Biocon Limited, Boehringer Ingelheim International GmbH, Catalent, Inc., Charles River Laboratories International, Inc., FUJIFILM Diosynth Biotechnologies, GenScript Biotech Corporation, KBI Biopharma, Inc., Lonza Group Ltd., Merck KGaA, Pfizer Inc., Horiba Ltd., Rentschler Biopharma SE, Stelis Biopharma, Thermo Fisher Scientific Inc., Rakuten Medical, Inc., WuXi Biologics, and Fresenius SE & Co. KGaA. Companies are focusing on expanding biologics manufacturing capacity, advanced bioprocessing technologies, flexible production platforms, and integrated development and manufacturing services.
Lonza Group Ltd.: An Emerging Market Leader
Lonza has strengthened its position through its broad range of contract development and manufacturing services for biologics and other advanced therapies. The company focuses on scalable manufacturing, advanced bioprocessing, process development, and integrated services that support biopharmaceutical products from early development through commercial production. These capabilities support Lonza’s strong position in the global biopharmaceutical contract manufacturing market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
North America Clinical Trial Imaging Market Size, Share, and Forecast 2034
Europe Clinical Trial Imaging Market Analysis, Trends, Forecast Up to 2034
Asia Pacific Clinical Trial Imaging Market Size, Share and Forecast to 2034
India Pharmaceutical Stability and Storage Services Market Size, Share & Trends | Industry Report, 2034
Healthcare Regulatory Affairs Outsourcing Market Size, Share, 2034
Facial Fat Transfer Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com